Plasma CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA4 in melanoma

ABSTRACT: Metastatic melanoma can be treated with anti-PD-1 monotherapy or in combination with anti-CTLA-4 or anti-Lag3. However, combination therapy is associated with a high risk of toxicity. Recently, we reported that high plasma soluble CD27 (sCD27) levels reflect the intratumoral interaction of CD70-CD27 and dysfunctional T cells in the tumor microenvironment of renal cell carcinoma. In this study, we first characterized the intratumoral expression of CD70 and CD27 in melanoma tumors and their interaction in vivo. We then reported a significant association between baseline sCD27 and anti-PD-1 resistance as assessed by progression-free survival, overall survival, or 12-month complete response in two prospective cohorts of melanoma patients. Multivariate analysis confirmed that sCD27 was independ

SUBMITTER: Ikuan Sam 

PROVIDER: S-SCDT-10_1038-S44321-025-00203-9 | biostudies-other |

REPOSITORIES: biostudies-other